filo Medpace Holdings (NASDAQ: MEDP ) fell ~11% in after-hours trading Monday after posting Q3 revenue results that missed the consensus estimate and provided a 2024 revenue guidance range that didn't include the consensus. While the clinical research-based drug and medical device development.
Back to Health Page
